Eight Departments: A preliminary formation of a collaborative system across the entire traditional Chinese medicine industry chain by 2030

Securities Times Reporter Han Zhongnan

On February 5th, the Ministry of Industry and Information Technology, the State-owned Assets Supervision and Administration Commission of the State Council, the State Administration of Financial Supervision, and six other departments jointly issued the “Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026–2030)” (hereinafter referred to as the “Plan”). The Plan clarifies development goals, key tasks, and保障措施 for the next five years, promoting comprehensive upgrades across the entire traditional Chinese medicine industry chain.

The Plan sets clear core development objectives by 2030, outlining a path for high-quality development of the traditional Chinese medicine industry. By then, a preliminary system for coordinated development across the entire industry chain will be established, with continuous enhancement of key medicinal raw material supply capabilities and significant improvements in digital intelligence and green practices.

Specifically, by 2030, 60 high-standard medicinal raw material production bases will be cultivated, five innovation centers for traditional Chinese medicine industry integrity will be built, a batch of innovative Chinese medicines will be approved for market launch, 10 new major varieties of Chinese patent medicines will be cultivated, 10 industry standards related to digital intelligence technology in the Chinese medicine industry will be drafted and revised, 20 typical cases of digital transformation and upgrading will be released, 20 smart factories will be built, and 10 green factories will be cultivated.

To ensure the achievement of these goals, the Plan deploys six major重点行动 and 15具体任务, focusing on precise efforts across all links of the产业链. In terms of raw material保障, it implements actions to improve quality and stabilize supply, guiding leading enterprises to build high-standard medicinal raw material bases in main production areas, supporting the construction of primary processing factories at origin, promoting automation production lines and “shared workshops,” and accelerating the drafting and revision of medicinal material quality standards. It also promotes the protection of rare medicinal resources and research on substitutes.

Innovation is the core动力 of产业升级. The Plan proposes implementing collaborative innovation攻关行动, integrating resources from enterprises, universities, and research institutions, establishing a Chinese medicine industry integrity and innovation center, and creating a合作模式 of “famous doctors, famous hospitals, famous schools, and famous enterprises.” Additionally, it encourages the application of artificial intelligence, big data, and other technologies to empower new drug研发,突破功效组分辨识 and formula optimization技术瓶颈, and promotes创新改良 of already marketed Chinese patent medicines. It also supports the transformation of Chinese medicine preparations in medical institutions into innovative drugs, cultivating new productive forces in the industry.

Regarding manufacturing capacity提升, the Plan emphasizes推动集约化生产 of Chinese medicine decoctions,完善质量标准体系, and accelerating digital and green transformation of Chinese medicine manufacturing. It aims to optimize the entire process quality追溯体系, ensuring traceability of sources, process monitoring, and traceability of product flow. For民族药, it implements振兴行动, leveraging民族药资源优势,完善质量控制体系,推动民族药产业现代化转型, and培育民族药名品.

Furthermore, the Plan includes推广中药名品 and培育卓越企业 actions. It advocates强化品牌保护,培育中成药 and decoction pieces’优势单品,推动“中药+”跨界融合, and发展大健康产品. It also emphasizes梯度培育领航企业 and优质中小企业, supporting enterprises in expanding into international markets, participating in the制定和修订中药国际标准, and提升中药品牌的国际影响力.

(Edited by: Wang Zhiqiang HF013)

【Disclaimer】This article only reflects the author’s personal views and has no relation to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions in the article and does not guarantee the accuracy, reliability, or completeness of the content. Readers are advised to use it as a reference and bear all responsibilities themselves. Email: news_center@staff.hexun.com